Published Online
on July 21, 2008

A more recent version of this article appeared on August 5, 2008

This Article Full Text (PDF) All Versions of this Article: 118/6/625    most recent CIRCULATIONAHA.107.759191v1 Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Request Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Dunlay, S. M. Articles by Roger, V. L. Search for Related Content PubMed PubMed Citation Articles by Dunlay, S. M. Articles by Roger, V. L. Pubmed/NCBI databases Gene GEO Profiles HomoloGene UniGene Compound via MeSH Substance via MeSH Medline Plus Health Information Heart Failure Related Collections Congestive Secondary prevention Growth factors/cytokines Epidemiology Related Article

Submitted on December 11, 2007
Accepted on May 29, 2008

Tumor Necrosis Factor- and Mortality in Heart Failure. A Community Study

Shannon M. Dunlay MD, Susan A. Weston MS, Margaret M. Redfield MD, Jill M. Killian BS, and Véronique L. Roger MD, MPH^*

From the Division of Cardiovascular Diseases (S.M.D., M.M.R., V.L.R.), and Department of Health Services Research (S.A.W., J.M.K., V.L.R.), Mayo Clinic and Foundation, Rochester, Minn.

^* To whom correspondence should be addressed. E-mail: roger.veronique{at}mayo.edu.

Background—Tumor necrosis factor- (TNF), an inflammatory cytokine, was reported to be elevated in trials of heart failure (HF) with reduced ejection fraction (EF) and associated with mortality. Whether this is true for HF with preserved EF is unknown, and community data are lacking. We evaluated the distribution of TNF, its association with baseline characteristics and mortality, and its benefit in assessing risk in community HF patients.

Methods and Results—Olmsted County residents with active HF from July 2004 to March 2007 (n=486; mean age, 76.7 years; EF 50%, 55%) were prospectively recruited. Clinical characteristics and TNF were measured. Elevated TNF (more than the assay limit of normal of 2.8 pg/mL) was present in 143 (29%). Higher TNF was associated with decreased creatinine clearance, nonsmoking status, anemia, and greater comorbidity (P_trend<0.05 for all). Mortality increased with increasing TNF (P=0.016), with 1-year mortality estimates of 16%, 18%, 23%, and 32% from the lowest to highest quartile, respectively. After adjustment for age, sex, and EF, the hazard ratios for death were 1.24, 1.37, and 1.90 from the second to the highest TNF quartile, respectively (P_trend=0.007). TNF contributed to risk assessment as indicated by increases in the area under the receiver-operating characteristic curves in all models examined (P<0.05 for all). Results did not differ by EF (P=0.60 interaction term of TNF and EF).

Conclusions—TNF was elevated in a large portion of community HF patients, was associated with a large decrease in survival, and provided a significant incremental increase in risk assessment above established indicators. TNF is useful for risk assessment in HF patients with preserved and reduced EF.

Key words: epidemiology • heart failure • inflammation • risk factors

Related Article:

Clinical Summaries
Circulation 2008 118: 607-608. [Extract] [Full Text]

This article has been cited by other articles:

				J. J.V. McMurray, J. Kjekshus, L. Gullestad, P. Dunselman, A. Hjalmarson, H. Wedel, M. Lindberg, F. Waagstein, P. Grande, J. Hradec, et al. Effects of Statin Therapy According to Plasma High-Sensitivity C-Reactive Protein Concentration in the Controlled Rosuvastatin Multinational Trial in Heart Failure (CORONA): A Retrospective Analysis Circulation, December 1, 2009; 120(22): 2188 - 2196. [Abstract] [Full Text] [PDF]

				J. F. Lula, M. O. d. C. Rocha, M. d. C. P. Nunes, A. L. P. Ribeiro, M. M. Teixeira, M. T. Bahia, and A. Talvani Plasma concentrations of tumour necrosis factor-alpha, tumour necrosis factor-related apoptosis-inducing ligand, and FasLigand/CD95L in patients with Chagas cardiomyopathy correlate with left ventricular dysfunction Eur J Heart Fail, September 1, 2009; 11(9): 825 - 831. [Abstract] [Full Text] [PDF]

				A. Zittermann, S. Frisch, H. K Berthold, C. Gotting, J. Kuhn, K. Kleesiek, P. Stehle, H. Koertke, and R. Koerfer Vitamin D supplementation enhances the beneficial effects of weight loss on cardiovascular disease risk markers Am. J. Clinical Nutrition, May 1, 2009; 89(5): 1321 - 1327. [Abstract] [Full Text] [PDF]

				S. Frantz, J. Bauersachs, and G. Ertl Post-infarct remodelling: contribution of wound healing and inflammation Cardiovasc Res, February 15, 2009; 81(3): 474 - 481. [Abstract] [Full Text] [PDF]